Stock Analiz

Lipocine Inc. LPCN

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.71Market cap $19M
Open the interactive analysis →

Lipocine Inc. (LPCN) is a healthcare company listed in the US with a market value of about $19M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$9M, a net margin of -249.2%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -31%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 92% below the current price.

About Lipocine

Lipocine is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $428031 in 2018 to $2M in 2025, growth of about 24.4% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 434% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S5.1
P/B0.9
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−92%

Growth and quality

Revenue growth (1 yr)-82.3%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-413.8%
ROIC (5-yr avg.)-30.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$4M$2M$11M-$3M$500000$16M$0$164990$428031$0$0
Net income-$9M-$10M$8352-$16M-$11M-$634399-$21M-$13M-$12M-$21M-$19M
Free cash flow——-$1M-$12M-$12M-$4M——-$12M-$17M-$18M
EPS (diluted)$-1.28$-1.69$0.00$-3.14$-2.15$-0.17$-6.43$-8.45$-9.30$-17.75$-17.59
Net margin-249.2%-487.1%0.1%573.6%-2151.7%-3.9%—-7883.7%-2724.1%——
ROIC—-56.6%-5.1%-69.5%-26.9%5.2%-67.9%-75.8%-45.4%-88.3%-58.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Lipocine stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 92% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Lipocine pay a dividend?

Not currently.

Is Lipocine a good stock to buy?

We do not give buy or sell advice. Lipocine scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.